Biocon announced that the 42nd Annual General Meeting (AGM) of the company will be held on 23 July 2020.

Powered by Capital Market - Live News

Biocon and DKSH announced that Biocon's subsidiary, Biocon Pharma and DKSH Business Unit Healthcare, have signed an agreement under which DKSH will sell and distribute seven of Biocon Pharma's generic formulations in Singapore and Thailand.

Under the terms of the agreement, DKSH will gain an exclusive license to register and commercialize these seven generic formulations from various therapeutic areas like diabetology, cardiology, oncology and immunology, which will be sold under Biocon's brand in Singapore and Thailand. DKSH will manage marketing and sales as well as logistics for Biocon Pharma, helping drive sales growth through its capabilities and strengths in the medical and pharmacy channels.

This development is in line with Biocon's strategy for expansion of its generic formulations business through licensing of its drug products in multiple markets. Thailand and Singapore are the two large markets in the South East Asia region.

Powered by Capital Market - Live News

Biocon's subsidiary, Biocon Pharma and DKSH Business Unit Healthcare, have signed an agreement under which DKSH will sell and distribute seven of Biocon Pharma's generic formulations in Singapore and Thailand.

Under the terms of the agreement, DKSH will gain an exclusive license to register and commercialize these seven generic formulations from various therapeutic areas like diabetology, cardiology, oncology and immunology, which will be sold under Biocon's brand in Singapore and Thailand. DKSH will manage marketing and sales as well as logistics for Biocon Pharma, helping drive sales growth through its capabilities and strengths in the medical and pharmacy channels.

This development is in line with Biocon's strategy for expansion of its generic formulations business through licensing of its drug products in multiple markets. Thailand and Singapore are the two large markets in the South East Asia region.

DKSH is the leading market expansion services provider with a focus on Asia. The group helps companies to grow across the business units healthcare, consumer goods, performance materials and technology.

Siddharth Mittal, CEO & managing director, Biocon, said: We are happy to partner with DKSH to commercialize Biocon's generic formulations pipeline in key South East Asian markets of Singapore and Thailand.

Biocon is a fully integrated, innovation-led global biopharmaceuticals company.

Powered by Capital Market - Live News

The drug is used to control high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type 1 diabetes. Semglee has an identical amino acid sequence to Sanofi's Lantus and is approved for the same indications.

Sanofi's total IQVIA sales for the 12 months ended 30 April 2020 were approximately $1.68 billion for Lantus 100 Units/mL Vial and approximately $4.33 billion for Lantus SoloSTAR Pen.

Mylan and Biocon Biologics co-developed insulin glargine (Semglee) has received regulatory approval in more than 45 countries around the world and is the third product approved by FDA through the Mylan-Biocon Biologics collaboration.

The two firms are exclusive partners on a broad portfolio of biosimilars and insulin analogs. Mylan has exclusive commercialization rights for insulin glargine in the U.S., Canada, Australia, New Zealand, the European Union and European Free Trade Association countries. Biocon Biologics, a subsidiary of Biocon, has exclusive rights for Japan and a few emerging markets, and co-exclusive commercialization rights with Mylan in the rest of the world.

Biocon is an innovation-led global biopharmaceuticals company. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe.

Powered by Capital Market - Live News